BOLDER BIOTECHNOLOGY RECEIVES FUNDING FROM THE NATIONAL CANCER INSTITUTE

Bolder BioTechnology, Inc. today announced that it has been awarded a $121,844 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute of The National Institutes of Health. The grant provides funds to evaluate effectiveness of the company's proprietary long acting gamma interferon analog for the treatment of ovarian cancer in animal models. The SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-12-2005/0004087549&EDATE=)